Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

RESEMBLE

Financiado

Long-read sequencing to resolve the missing heritability in patients suspected o...

Long-read sequencing to resolve the missing heritability in patients suspected of PTEN hamartoma tumour syndrome Individuals with a genetic tumour risk syndrome are at high risk to develop cancer. One of these syndromes is PTEN hamartoma tumour syndrome (PHTS). PHTS is associated with pathogenic variants (PVs) in the PTEN gene. Unfortunately... ver más

14/05/2024

RADBOUDUMC

188K€

Presupuesto del proyecto: 188K€

Líder del proyecto

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRU... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-14

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021

I+D

Cerrada hace 3 años

0% 100% 100%

1 Participantes

RADBOUDUMC

187.62K€ | Lider

Proyectos interesantes

SAF2017-89116-R MALFORMATIONES VASCULARES ONCOGENICAS DESDE LA BIOLOGIA HAST... 242K€ Cerrado

OR-HMC Assay for cancer diagnostics by quantification of 5hmC 150K€ Cerrado

SAF2016-80157-R MECANISMOS MOLECULARES DE PROGRESION TUMORAL EN MODELOS DE N... 157K€ Cerrado

EpiCblood Towards early cancer detection and tumor classification usin... 1M€ Cerrado

EpiCancer Comprehensive Platform for the Functional Characterization o... 2M€ Cerrado

EQC2018-004733-P ADQUISIÓN DE EQUIPO PARA IDENTIFICACIÓN Y RECUPERACIÓN DE CÉ... 171K€ Cerrado

Últimas noticias

30-11-2024: Cataluña Gestión For... Se ha cerrado la línea de ayuda pública: Gestión Forestal Sostenible para Inversiones Forestales Productivas para el organismo:

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

Duración del proyecto: 24 meses Fecha Inicio: 2022-04-28
Fecha Fin: 2024-05-14

Presupuesto del proyecto 188K€

Descripción del proyecto Individuals with a genetic tumour risk syndrome are at high risk to develop cancer. One of these syndromes is PTEN hamartoma tumour syndrome (PHTS). PHTS is associated with pathogenic variants (PVs) in the PTEN gene. Unfortunately, in the majority of patients suspected of PHTS no PV in PTEN is identified. These patients are considered PHTS-like. The low diagnosis rate in this group of patients suggests the possibility of PVs in regions of PTEN that are not covered in routine diagnostics or suggests that PVs in other genes in the PI3K/AKT/mTOR pathway result in PHTS-like disease. In order to identify the missing heritability in PHTS I aim to develop a long-read sequencing (LRS) approach for PHTS-like patients, which will go beyond the currently state-of-the-art short-read sequencing approaches. I will O1) develop a PTEN-targeted LRS assay and O2) perform this assay on a highly selective cohort of PHTS-like families (n=94). I then will O3) perform whole genome LRS on 25 families that were not solved by targeted LRS to identify novel gene-disease associations. At last, I will O4) validate these new associations in a wider cohort. Via this work, I will improve the diagnostic yield for PHTS by identifying novel genetic mechanisms and genes underlying disease in PHTS-like patients. The unique interdisciplinary structure of the Department of Human Genetics at Radboudumc will allow to rapidly implement genetic testing for the newly identified genetic causes for PHTS. Identification of the precise underlying cause of PHTS will enable cascade genetic testing of at-risk family members to determine their status for the causal variant and thus, risk of disease to them and any future off-spring. Furthermore, this approach will allow the implementation of preventive care strategies for the family members at risk. Overall, my proposal will facilitate a personalized care approach for PHTS(-like) patients and their families for improved clinical outcomes and reduced disease morbidity

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores